Market Research Logo

Acute Ischemic Stroke - Pipeline Review, H2 2015

Acute Ischemic Stroke - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Acute Ischemic Stroke - Pipeline Review, H2 2015’, provides an overview of the Acute Ischemic Stroke’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acute Ischemic Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Ischemic Stroke and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Acute Ischemic Stroke
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Acute Ischemic Stroke and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Acute Ischemic Stroke products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Acute Ischemic Stroke pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Acute Ischemic Stroke
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Acute Ischemic Stroke pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Acute Ischemic Stroke Overview
Therapeutics Development
Pipeline Products for Acute Ischemic Stroke - Overview
Acute Ischemic Stroke - Therapeutics under Development by Companies
Acute Ischemic Stroke - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Acute Ischemic Stroke - Products under Development by Companies
Acute Ischemic Stroke - Companies Involved in Therapeutics Development
AB Science SA
AstraZeneca Plc
Biogen, Inc.
D-Pharm Ltd.
Daiichi Sankyo Company, Limited
DiaMedica Inc.
Digna Biotech, S.L.
Glucox Biotech AB
Grifols, S.A.
Lumosa Therapeutics Co., Ltd.
Mitsubishi Tanabe Pharma Corporation
Pharmicell Co., Ltd.
PhytoHealth Corporation
Remedy Pharmaceuticals, Inc.
Simcere Pharmaceutical Group
Stemedica Cell Technologies, Inc.
ZZ Biotech, LLC
Acute Ischemic Stroke - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
3K3A-APC - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cerecellgram-Stroke - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DB-017 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DM-199 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DS-1040 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
glyburide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HBN-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Human Plasmin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LT-3001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
masitinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mesenchymal Stem Cells - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MP-124 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
natalizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Peptide to Agonize GHSR-1a for Sepsis, Acute Radiation Syndrome and Acute Ischemic Stroke - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PHN-014 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Plasmin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SIM-071201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule-1 to Inhibit NOX-4 for Acute Ischemic Stroke - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule-2 to Inhibit NOX-4 for Acute Ischemic Stroke - Drug Profile
Product Description
Mechanism of Action
R&D Progress
THR-18 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ticagrelor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TS-01 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Acute Ischemic Stroke - Recent Pipeline Updates
Acute Ischemic Stroke - Dormant Projects
Acute Ischemic Stroke - Discontinued Products
Acute Ischemic Stroke - Product Development Milestones
Featured News & Press Releases
Jun 01, 2015: Thrombolytic Science to Collaborate With National Institutes of Health to Test a Novel Thrombolytic Regimen for the Treatment of Acute Ischemic Stroke in Phase IIa Clinical Trial
Mar 19, 2015: DiaMedica to Present at the 12th Annual BIO Asia International Conference
Dec 18, 2014: D-Pharm Achieves Primary End-point in Phase 2 Clinical Study of THR-18 in Acute Stroke Patients Treated With tPA
Nov 04, 2014: D-Pharm Reports First Results From its Phase 2 Clinical Study of THR-18 In Acute Stroke Patients Treated with tPA
Aug 19, 2014: US Department of Justice Closes Investigation into PLATO Clinical Trial for BRILINTA
Jun 02, 2014: D-Pharm Reports Completion of the Second Dose Tier in its Phase 2 Clinical Study of THR-18 in Acute Stroke Patients Treated with the Thrombolytic Drug tPA
Apr 22, 2014: ZZ Biotech Announces Phase 2 Trial with 3K3A-APC in Stroke; Funds Will Be Provided by NIH and Broadview Ventures
Mar 04, 2014: D-Pharm reports the successful interim analysis of its Phase 2 clinical study of THR-18 in acute stroke patients
Jan 21, 2014: D-Pharm completes recruitment of patients into the first dosage tier of its Phase 2 study with THR-18 in acute stroke patients treated with tPA
Jan 08, 2014: D-Pharm receives grant to support the development of its Phase 2 product, THR-18
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Acute Ischemic Stroke, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Acute Ischemic Stroke - Pipeline by AB Science SA, H2 2015
Acute Ischemic Stroke - Pipeline by AstraZeneca Plc, H2 2015
Acute Ischemic Stroke - Pipeline by Biogen, Inc., H2 2015
Acute Ischemic Stroke - Pipeline by D-Pharm Ltd., H2 2015
Acute Ischemic Stroke - Pipeline by Daiichi Sankyo Company, Limited, H2 2015
Acute Ischemic Stroke - Pipeline by DiaMedica Inc., H2 2015
Acute Ischemic Stroke - Pipeline by Digna Biotech, S.L., H2 2015
Acute Ischemic Stroke - Pipeline by Glucox Biotech AB, H2 2015
Acute Ischemic Stroke - Pipeline by Grifols, S.A., H2 2015
Acute Ischemic Stroke - Pipeline by Lumosa Therapeutics Co., Ltd., H2 2015
Acute Ischemic Stroke - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2015
Acute Ischemic Stroke - Pipeline by Pharmicell Co., Ltd., H2 2015
Acute Ischemic Stroke - Pipeline by PhytoHealth Corporation, H2 2015
Acute Ischemic Stroke - Pipeline by Remedy Pharmaceuticals, Inc., H2 2015
Acute Ischemic Stroke - Pipeline by Simcere Pharmaceutical Group, H2 2015
Acute Ischemic Stroke - Pipeline by Stemedica Cell Technologies, Inc., H2 2015
Acute Ischemic Stroke - Pipeline by ZZ Biotech, LLC, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Acute Ischemic Stroke Therapeutics - Recent Pipeline Updates, H2 2015
Acute Ischemic Stroke - Dormant Projects, H2 2015
Acute Ischemic Stroke - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Acute Ischemic Stroke, H2 2015 10
Number of Products under Development by Companies, H2 2015 11
Comparative Analysis by Late Stage Development, H2 2015 13
Comparative Analysis by Clinical Stage Development, H2 2015 14
Assessment by Monotherapy Products, H2 2015 35
Number of Products by Top 10 Targets, H2 2015 36
Number of Products by Stage and Top 10 Targets, H2 2015 36
Number of Products by Top 10 Mechanism of Actions, H2 2015 38
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 38
Number of Products by Routes of Administration, H2 2015 40
Number of Products by Stage and Routes of Administration, H2 2015 40
Number of Products by Molecule Types, H2 2015 42
Number of Products by Stage and Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report